Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001088875-26-000056
Filing Date
2026-08-04
Accepted
2026-08-04 09:11:07
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5910
  Complete submission text file 0001088875-26-000056.txt   7658
Mailing Address 3 HAYMARKET SQUARE EDINBURGH United Kingdom EH3 8RY
Business Address 3 HAYMARKET SQUARE EDINBURGH United Kingdom EH3 8RY 00441312752000
BAILLIE GIFFORD & CO (Filed by) CIK: 0001088875 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: SCHEDULE 13G/A

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90223 | Film No.: 261235929
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)